Descrizione del progetto
Pancreas artificiale: una terapia migliore per i bambini con diabete
Il diabete di tipo 1 nei bambini può avere numerose conseguenze sulla salute, e pertanto richiede un attento controllo dei livelli di glucosio. I microinfusori forniscono un apporto continuo di insulina per tutto il giorno, ma l’utente deve regolarne il dosaggio in base ai livelli di glucosio nel sangue. Di contrasto, il pancreas artificiale è un sistema a circuito chiuso che misura automaticamente i livelli di glucosio e ne calcola il dosaggio corretto. Il progetto KidsAP, finanziato dall’Unione Europea, studierà l’efficacia di un pancreas artificiale nei bambini di età compresa tra 1 e 7 anni affetti da diabete di tipo 1. I ricercatori confronteranno il dispositivo con la terapia standard che prevede l’uso del microinfusore di insulina, valutando la qualità della vita e conducendo interviste. Ci si attende che i risultati del progetto migliorino l’assistenza sanitaria per i bambini con questa patologia.
Obiettivo
TYPE 1 DIABETES is one of the most COMMON CHRONIC diseases in children with a RAPID increase in number of cases particularly in young children. Type 1 diabetes is associated with LIFE-LONG dependency on insulin administration. POOR glucose control leads to diabetes COMPLICATIONS, e.g. eye, heart, kidney disease, including BRAIN changes in young children. Episodes of VERY LOW glucose levels may be life threatening and are a major complication.
The ARTIFICIAL PANCREAS addresses the problem of LOW and HIGH glucose levels by delivering insulin BELOW and ABOVE pre-set amounts according to real-time sensor GLUCOSE levels, combining glucose SENSOR, insulin PUMP, and CONTROL ALGORITHM. The Artificial pancreas promises to TRANSFORM management of type 1 diabetes but EVIDENCE supporting its use during FREE LIVING in YOUNG CHILDREN is MISSING.
The project evaluates the biomedical, psychosocial, and cost effectiveness of NOVEL INDIVIDUALISED artificial pancreas in young children aged 1 to 7 years with type 1 diabetes. Following a PILOT (n=24), in the MAIN study (n=94) half of the participants (n=47) will be treated over 12 MONTHS by the ARTIFICIAL PANCREAS and the other half (n=47) by STATE-OF-THE-ART PREDICTIVE LOW GLUCOSE MANAGEMENT insulin pump therapy. Each treatment will last ONE YEAR. QUALITY OF LIFE will be assessed and semi-structured INTERVIEWS conducted to understand the impact on daily life. HEALTH TECHNOLOGY ASSESSMENT will support reimbursement.
The project will OPTIMISE artificial pancreas and SPEARHEAD SYSTEM-WIDE improvements in health care quality and health outcomes in YOUNG CHILDERN with TYPE 1 DIABETES who live with the disease LONGEST. By IMPROVING THERAPEUTIC OUTCOMES, the project will CHANGE clinical practice and INFLUENCE national and international treatment guidelines making the artificial pancreas WIDELY ACCEPTABLE as the state-of-art treatment modality in young children.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-2016-RTD
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
CB2 1TN Cambridge
Regno Unito